CohBar, Inc. Stock price

Equities

CWBR

US19249J3077

Biotechnology & Medical Research

Delayed OTC Markets 10:15:50 2024-03-28 am EDT 5-day change 1st Jan Change
0.8801 USD -11.99% Intraday chart for CohBar, Inc. +15.74% +18.93%
Sales 2021 - Sales 2022 - Capitalization 4.93M
Net income 2021 -15M Net income 2022 -12M EV / Sales 2021 -
Net cash position 2021 25.88M Net cash position 2022 15.74M EV / Sales 2022 -
P/E ratio 2021
-1.51 x
P/E ratio 2022
-0.4 x
Employees 10
Yield 2021 *
-
Yield 2022
-
Free-Float 84.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day-11.99%
1 week+15.74%
Current month+15.77%
1 month+15.79%
3 months+10.22%
6 months-70.27%
Current year+18.93%
More quotes
1 week
0.76
Extreme 0.7602
1.00
1 month
0.76
Extreme 0.7601
1.00
Current year
0.72
Extreme 0.72
1.01
1 year
0.58
Extreme 0.58
6.90
3 years
0.58
Extreme 0.58
68.10
5 years
0.58
Extreme 0.58
127.50
10 years
0.58
Extreme 0.58
323.67
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 22-01-03
Members of the board TitleAgeSince
Director/Board Member 63 Nov. 05
More insiders
Date Price Change Volume
24-03-28 0.8801 -11.99% 593
24-03-27 1 +31.51% 4,546
24-03-26 0.7604 +0.03% 2,175
24-03-25 0.7602 -0.03% 2,425
24-03-21 0.7604 -0.03% 757

Delayed Quote OTC Markets, March 28, 2024 at 10:15 am EDT

More quotes
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock CohBar, Inc. - OTC Markets